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Fig. S1 In vivo dose finding of perifosine
As an index of systemic toxicity, changes in body weight after  oral perifosine administration were 
assessed. (a) One 3-days course of oral (PO) perifosine at 35 mg/Kg/day caused a significant loss of 
body weight and was lethal for 2/5 of treated animals. (b) One 3-days course of oral (PO) perifosine at 
25 mg/Kg/day caused a significant loss of body weight and was lethal for 1/6 of treated animals. (c) 
Two 5-days courses of oral (PO) perifosine at 15 mg/Kg/day and (d) two 5-days courses of oral (PO) 
perifosine at 10 mg/Kg/day were well tolerated and did not cause any significant loss of body weight. 
Skulls indicate dead animals.  Autopsy of dead animals revealed swollen stomach and intestines and 
yellowish-white brittle liver, suggesting gastrointestinal toxicity as cause of death
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Fig. S2 Perifosine does not affect phospho-Akt expression in healthy organs 
NOD/SCID mice bearing subcutaneous tumor nodules were treated with perifosine at 15 mg/kg (once 
daily for 5 days, PO), or the vehicle control. Immediately prior to sacrifice, mice were IV injected with 
0.2  ml  of  sulfo-NHS-LC-biotin  (5  mg/ml)  to  biotinylate  functional  vasculature.  Healthy  organs 
(including  lungs,  livers  and  spleens)  were  then  harvested,  freshly snap-frozen  in  isopentane and 
analyzed for phospho-Akt expression. Representative confocal images of lungs, livers and spleens from 
perifosine-untreated  and treated mice processed by triple immunofluorescence staining are shown. 
Biotinylated endothelial cells were detected by green staining with Alexa 488-conjugated streptavidin; 
phosphorylated Akt was detected by red coloration incubating sections with an anti-mouse phospho-
Akt antibody followed by the appropriate Alexa Fluor 568-conjugated secondary antibody; cell nuclei 
were detected in blue with TO-PRO-3 nuclear dye. Arrowheads indicate the field magnified in inserted 
images. Objective lens, original magnification: 1.0 NA oil objective, 40x; scale bar 25 µm. Inserted 
images objective lens, original magnification: 1.4 NA oil objective, 60x; scale bar 5µm 
Fig. S3 DR5 expression in TECs is modulated by perifosine at mRNA level
CD146+ subpopulations obtained from SU-DHL-4V tumor nodules from mice receiving the vehicle 
control or perifosine at 15 mg/kg (once daily for 5 days, PO) were processed for RT-PCR analysis to 
evaluate relative fold increase in DR5 expression. Data in the graph are the results obtained by the 
analysis of TECs derived from a pool of three tumors per group   
Fig. S4 Tumor cells differentially affect TECs phenotype
2H-11 cells were co-cultured  for 72 hours with either SU-DHL-4V or KMS-11 cells (2H-11: tumor 
cells ratio 1:4) in presence (black bars) or absence (white bars) of perifosine 5 µM and analyzed for 
DR5 expression by flow cytometric analysis. Represented are the mean  ± SD percentage of positive 
cells. The percentages of positive cells were measured according to gates set on the basis of isotype 
control  
Fig.  S5  Perifosine-induced enhancement of  the vascular disruption activity of  CD34-TRAIL+ 
cells is tumor restricted
NOD/SCID  mice  bearing  subcutaneous  tumor  nodules  were  randomly  assigned  to  the  different 
treatment groups consisting of the administration of one injection of CD34-TRAIL+   cells (3  x 106 
cells/mouse,  IV);  perifosine  at  15  mg/kg  (once  daily  for  5  days,  PO);  CD34-TRAIL+ cells  in 
combination  with  perifosine;  or  the  vehicle  control.  Seventy-two  hours  after  CD34-TRAIL+ cell 
treatment and three hours after  the last  perifosine administration,  healthy organs (including lungs, 
livers, spleens and femurs) were harvested, fixed in formalin, embedded in paraffin  and analyzed for 
the presence of hemorrhages and necrosis. Representative histological images of healthy organs from 
untreated and treated animals are shown. Hematoxylin and eosin staining demonstrates the absence of 
tissue or  vascular damage. Objective lens, original magnification: 0.40 NA dry objective, 10x; scale 
bar: 200µm  
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Fig. S6 In vitro and in vivo effects of perifosine on tumor cells
(a) SU-DHL-4V and KMS-11  cells were exposed for  24,  48 and 72 hours to increasing doses of 
perifosine  and  analyzed  by  Annexin-V–fluorescein  isothiocyanate/propidium  iodide  (PI)  double 
staining to detect  Annexin-V−/PI− viable cells by flow cytometry. The mean  ± SD percentages are 
shown.  (b)  NOD/SCID mice bearing subcutaneous  tumor  nodules  were  randomly assigned to the 
different treatment groups consisting of the administration of perifosine at 15 mg/kg (once daily for 5 
days, PO) or the vehicle control. Three hours after the last perifosine administration, tumor nodules 
were harvested,  fixed in formalin, embedded in paraffin  and analyzed for  the presence of apoptotic 
cells by TUNEL staining. Representative histological images of TUNEL-stained tumors sections from 
untreated and perifosine-treated animals are shown. Objective lens, original magnification: 0.40 NA 
dry objective,  20x;  scale  bar:  50µm.  (c)  TUNEL stained  SU-DHL-4V and  KMS-11  whole  tumor 
sections were digitally acquired and images analyzed using ImageJ for quantification of the percentage 
of apoptotic cells.  At least three tumor sections from different animals were analyzed per  treatment 
group. Each dot represents the value obtained from the analysis of a single tissue field, and the lines 
indicate the mean values. *** P < 0.001 compared with controls
